A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors
Clinical trial NCT06656390 · RECRUITING
Trial details
- NCT number
- NCT06656390
- Sponsor
- Shanghai Allink Biotherapeutics Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-24
- Primary completion
- 2027-10-22
- Enrollment
- 202
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.